In one paragraphArticle in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Evangelia PantazakaLaboratory of Biochemistry/Metastatic Signaling, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, University Campus, Patras, Greece.ORCID https://orcid.org/0000-0001-6737-8428 Dimitrios PapakonstantinouLaboratory of Biochemistry/Metastatic Signaling, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, University Campus, Patras, Greece.ORCID https://orcid.org/0009-0000-5074-2289 Argyro RoumeliotouLaboratory of Biochemistry/Metastatic Signaling, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, University Campus, Patras, Greece.
Sotirios TsakasLaboratory of Biochemistry/Metastatic Signaling, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, University Campus, Patras, Greece.
Nefeli ZacharopoulouMedical Science Liaison MSL Oncology & Rare Diseases, Medical Department, Ipsen Greece & Cyprus, IPSEN SP LLC, 63 Agiou Dimitriou Str., Alimos-Athens, Greece.
Stuart S MartinDepartment of Pharmacology and Physiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Athanasios KotsakisDepartment of Medical Oncology, General University Hospital of Larissa, Larissa, Greece.
Galatea KallergiLaboratory of Biochemistry/Metastatic Signaling, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, University Campus, Patras, Greece.ORCID https://orcid.org/0000-0001-9825-3871 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsArtesunateDrug RepositioningNeoplastic Cells, CirculatingCell Line, TumorCell SurvivalDisease ProgressionHumansNeoplasm MetastasisProto-Oncogene MasAntineoplastic AgentsArtesunateMAS1 protein, humanProto-Oncogene MasanoikisapoptosisArtesunatecirculating tumor cellsmetastasissmall-cell lung cancer (SCLC)TetherChip
Identifiers
PMID42232605
PMCPMC13223190
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390